Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hamlin, P.J.
610  Ergebnisse:
Personensuche X
?
1

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology.  41 (2023)  S2 - p. 351-353 , 2023
Link: https://doi.org/10.1002/..
 
?
2

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:

Torka, P. ; Feldman, T. ; Savage, K....
Hematological Oncology.  41 (2023)  S2 - p. 161-162 , 2023
Link: https://doi.org/10.1002/..
 
?
3

S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUT..:

Wang, M. L. ; Jurczak, W. ; Jerkeman, M....
HemaSphere.  6 (2022)  - p. 110-111 , 2022
Link: https://doi.org/10.1097/..
 
?
4

CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAG..:

Sha, F. ; Okwali, M. ; Alperovich, A....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglo..:

Kumar, Anita ; Bantilan, K.S. ; Jacob, A.P....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  4 - p. 230-237.e12 , 2021
Link: https://doi.org/10.1016/..
 
?
6

PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VE..:

Kumar, A. ; Batlevi, C. ; Drullinsky, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

User Experience Design to Synchronize Government Acquisitio..:

, In: 2020 Systems and Information Engineering Design Symposium (SIEDS),
Ecelbarger, A. N. ; Hamlin, P. D. ; McGrath, S. C.... - p. 1-6 , 2020
Link: https://doi.org/10.1109/..
 
?
8

INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORM..:

Rajeeve, S. ; Bobillo, S.V. ; Zelenetz, A.D....
Hematological Oncology.  37 (2019)  S2 - p. 264-266 , 2019
Link: https://doi.org/10.1002/..
 
?
9

RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERD..:

Smith, S.D. ; Munoz, J. ; Stevens, D.A....
Hematological Oncology.  37 (2019)  S2 - p. 61-62 , 2019
Link: https://doi.org/10.1002/..
 
?
10

A PHASE 1/2 STUDY OF MT‐3724 TO EVALUATE SAFETY, PHARMACODY..:

Burnett, C.A. ; Hamlin, P. ; Dabovic, K...
Hematological Oncology.  37 (2019)  S2 - p. 566-566 , 2019
Link: https://doi.org/10.1002/..
 
?
11

CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LA..:

Bobillo, S. ; Joffe, E. ; Lavery, J....
Hematological Oncology.  37 (2019)  S2 - p. 251-252 , 2019
Link: https://doi.org/10.1002/..
 
?
12

IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE ..:

Batlevi, C.L. ; Sha, F. ; Alperovich, A....
Hematological Oncology.  37 (2019)  S2 - p. 152-153 , 2019
Link: https://doi.org/10.1002/..
 
?
13

Editorial: probiotics in inflammatory bowel disease—wrong o..:

Gracie, D. J. ; Derwa, Y. ; Hamlin, P. J..
Alimentary Pharmacology & Therapeutics.  46 (2017)  6 - p. 633-634 , 2017
Link: https://doi.org/10.1111/..
 
?
14

BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTI..:

Moskowitz, A.J. ; Schöder, H. ; Gavane, S....
Hematological Oncology.  35 (2017)  S2 - p. 36-37 , 2017
Link: https://doi.org/10.1002/..
 
?
15

P.11.2: The Impact of Infliximab Therapeutic Drug Monitorin..:

Selinger, C.P. ; Lenti, M.V. ; Clark, T....
Digestive and Liver Disease.  49 (2017)  - p. e202 , 2017
Link: https://doi.org/10.1016/..
 
1-15